Supplementary materials: Estimating the risk of thrombotic events in people with congenital hemophilia A using US claims data

dataset

posted on 2024-01-03, 17:01 authored by Imi Faghmous, Francis Nissen, Peter J. Kuebler, Carlos Flores, Steven W Pipe

These are peer-reviewed supplementary tables for the article 'Estimating the risk of thrombotic events in people with congenital hemophilia A using US claims data' published in the Journal of Comparative Effectiveness Research.<table><tr><td><ul><li>Supplemental Table 1A. ICD-9-CM and ICD-10-CM codes used to identify myocardial infarction.</li><li>Supplemental Table 1B. ICD-9-CM and ICD-10-CM codes used to identify pulmonary embolism.</li><li>Supplemental Table 1C. ICD-9-CM and ICD-10-CM codes used to identify ischemic stroke.</li><li>Supplemental Table 1D. ICD-9-CM and ICD-10-CM codes used to identify deep vein thrombosis.</li><li>Supplemental Table 1E. ICD-9-CM and ICD-10-CM codes used to identify device-related thrombosis.</li><li>Supplemental Table 2A. ICD-9-CM and ICD-10-CM codes to identify HIV.</li><li>Supplemental Table 2B. ICD-9-CM and ICD-10-CM codes to identify hepatitis C.</li><li>Supplemental Table 3. Adjusted IRR (95% CI) by age group.</li></ul></td></tr></table>Summary: Aim: Compare thrombotic risk in people with congenital hemophilia A (PwcHA) to the general non-hemophilia A (HA) population. Patients & methods: US claims databases were analyzed to identify PwcHA. Incidence rates of myocardial infarction, pulmonary embolism, ischemic stroke, deep vein thrombosis and device-related thrombosis were compared with a matched cohort without HA. Results: Over 3490 PwcHA were identified and 16,380 individuals matched. PwcHA had a similar incidence of myocardial infarction and pulmonary embolism compared with the non-HA population, but a slightly higher incidence of ischemic stroke and deep vein thrombosis. The incidence of device-related thrombosis was significantly higher in PwcHA. Conclusion: This analysis suggests that PwcHA are not protected against thrombosis, and provides context to evaluate thrombotic risk of HA treatments.